Nervous System Diseases clinical trials at UC Health

• EDS in Ataxia Telangiectasia Patients

  open to eligible people ages 6 years and up

  This is an international, multi-center, one-year, randomized, prospective, double-blind, placebo-controlled, phase III study, designed to assess the effect of two non-overlapping dose ranges of EDS EP, administered by IV infusion once per month, on neurological symptoms of patients with Ataxia Telangiectasia.

  at UCLA

• Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects

  Sorry, in progress, not accepting new patients

  Glioblastoma (GBM) and gliosarcoma (GS) are the most common and aggressive forms of malignant brain tumor in adults and can be resistant to conventional therapies. The purpose of this Phase II study is to evaluate how well a recurrent glioblastoma or gliosarcoma tumor responds to one injection of DNX-2401, a genetically modified oncolytic adenovirus, when delivered directly into the tumor followed by the administration of intravenous pembrolizumab (an immune checkpoint inhibitor) given every 3 weeks for up to 2 years or until disease progression. Funding Source-FDA OOPD

  at UCLA

• Long-Term Outcomes of Ataluren in Duchenne Muscular Dystrophy

  Sorry, in progress, not accepting new patients

  This study is a long-term study of ataluren in participants with nonsense mutation Duchenne muscular dystrophy.

  at UC Davis UCSF

• Safety and Efficacy Study of VY-AADC01 for Advanced Parkinson's Disease

  Sorry, in progress, not accepting new patients

  Safety and efficacy of AADC gene transfer in participants with Parkinson's disease.

  at UCSF

Last updated: November 10, 2020